Leukotriene B4/leukotriene B4 receptor pathway is involved in hepatic microcirculatory dysfunction elicited by endotoxin. 2008

Sohei Ito, and Yoshiya Ito, and Hiroyuki Katagiri, and Tatsunori Suzuki, and Sumio Hoka, and Takehiko Yokomizo, and Takao Shimizu, and Masataka Majima
Department of Pharmacology, Kitasato University of Medicine, Kanagawa, Japan.

Leukotrienes (LTs), metabolites of arachidonic acid through 5-lipoxygenase (5-LOX), have been known to play a role in leukocyte recruitment. However, the contribution of LTB4 to liver microcirculatory dysfunction during endotoxemia remains unknown. LTB4 receptor (BLT1) has been identified as a high-affinity receptor specific for LTB4. The present study was conducted to examine the roles of LTB4 and BLT1 in hepatic microcirculatory dysfunction elicited by LPS in mice. The number of leukocytes adhering to the endothelial cells of the hepatic microvessels and perfused sinusoids was determined 4 h after the administration of LPS (0.3 mg/kg, i.v.) to male C57Bl6 mice by in vivo microscopy. A 5-LOX synthase inhibitor, AA-861 (10 or 100 mg/kg, s.c.), was administered 30 min before LPS injection. BLT1 knockout mice were used to investigate whether LPS-induced hepatic microcirculatory dysfunction is mediated by BLT1 signaling. The expression of 5-LOX, intercellular adhesion molecule (ICAM) 1, and TNF-[alpha] in the liver was measured by real-time reverse-transcriptase-polymerase chain reaction. The administration of LPS caused significant accumulation of leukocyte adhesion to the hepatic microvessels and reduced sinusoidal perfusion when compared with saline-treated mice. The hepatic microcirculatory dysfunction elicited by LPS was minimized in mice pretreated with AA-861 or in BLT1 knockout mice. This was associated with the suppression of hepatic expression of 5-LOX, ICAM-1, and TNF-[alpha]. These findings suggest that the LTB4/BLT1 pathway mediates hepatic microcirculatory dysfunction by enhanced expression of ICAM-1 and TNF-[alpha] in a murine model of endotoxemia.

UI MeSH Term Description Entries
D007975 Leukotriene B4 The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) 5,12-HETE,5,12-diHETE,LTB4,Leukotriene B,Leukotriene B-4,Leukotrienes B,5,12 HETE,5,12 diHETE,B-4, Leukotriene,Leukotriene B 4
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008833 Microcirculation The circulation of the BLOOD through the MICROVASCULAR NETWORK. Microvascular Blood Flow,Microvascular Circulation,Blood Flow, Microvascular,Circulation, Microvascular,Flow, Microvascular Blood,Microvascular Blood Flows,Microvascular Circulations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016859 Lipoxygenase Inhibitors Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. 5-Lipoxygenase Inhibitor,Lipoxygenase Inhibitor,12-Lipoxygenase Inhibitors,15-Lipoxygenase Inhibitors,5-Lipoxygenase Inhibitors,Arachidonate 12-Lipoxygenase Inhibitors,Arachidonate 15-Lipoxygenase Inhibitors,Arachidonate 5-Lipoxygenase Inhibitors,Inhibitors, Lipoxygenase,12 Lipoxygenase Inhibitors,12-Lipoxygenase Inhibitors, Arachidonate,15 Lipoxygenase Inhibitors,15-Lipoxygenase Inhibitors, Arachidonate,5 Lipoxygenase Inhibitor,5 Lipoxygenase Inhibitors,5-Lipoxygenase Inhibitors, Arachidonate,Arachidonate 12 Lipoxygenase Inhibitors,Arachidonate 15 Lipoxygenase Inhibitors,Arachidonate 5 Lipoxygenase Inhibitors,Inhibitor, 5-Lipoxygenase,Inhibitor, Lipoxygenase,Inhibitors, 12-Lipoxygenase,Inhibitors, 15-Lipoxygenase,Inhibitors, 5-Lipoxygenase,Inhibitors, Arachidonate 12-Lipoxygenase,Inhibitors, Arachidonate 15-Lipoxygenase,Inhibitors, Arachidonate 5-Lipoxygenase
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D056486 Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment. Drug-Induced Liver Injury,Liver Injury, Drug-Induced,Acute Liver Injury, Drug-Induced,Chemically-Induced Liver Toxicity,Drug-Induced Acute Liver Injury,Drug-Induced Liver Disease,Hepatitis, Drug-Induced,Hepatitis, Toxic,Liver Injury, Drug-Induced, Acute,Toxic Hepatitis,Acute Liver Injury, Drug Induced,Chemically Induced Liver Toxicity,Chemically-Induced Liver Toxicities,Disease, Drug-Induced Liver,Diseases, Drug-Induced Liver,Drug Induced Acute Liver Injury,Drug Induced Liver Disease,Drug Induced Liver Injury,Drug-Induced Hepatitides,Drug-Induced Hepatitis,Drug-Induced Liver Diseases,Drug-Induced Liver Injuries,Hepatitides, Drug-Induced,Hepatitides, Toxic,Hepatitis, Drug Induced,Injuries, Drug-Induced Liver,Injury, Drug-Induced Liver,Liver Disease, Drug-Induced,Liver Diseases, Drug-Induced,Liver Injuries, Drug-Induced,Liver Injury, Drug Induced,Liver Toxicities, Chemically-Induced,Liver Toxicity, Chemically-Induced,Toxic Hepatitides,Toxicities, Chemically-Induced Liver,Toxicity, Chemically-Induced Liver
D018102 Receptors, Leukotriene B4 A class of cell surface leukotriene receptors with a preference for leukotriene B4. Leukotriene B4 receptor activation influences chemotaxis, chemokinesis, adherence, enzyme release, oxidative bursts, and degranulation in polymorphonuclear leukocytes. There are at least two subtypes of these receptors. Some actions are mediated through the inositol phosphate and diacylglycerol second messenger systems. LTB4 Receptors,Leukotriene B4 Receptors,LTB4 Receptor,Leukotriene B4 Receptor,Receptor, LTB4,Receptor, Leukotriene B4,Receptors, LTB4

Related Publications

Sohei Ito, and Yoshiya Ito, and Hiroyuki Katagiri, and Tatsunori Suzuki, and Sumio Hoka, and Takehiko Yokomizo, and Takao Shimizu, and Masataka Majima
October 1990, Biochimica et biophysica acta,
Sohei Ito, and Yoshiya Ito, and Hiroyuki Katagiri, and Tatsunori Suzuki, and Sumio Hoka, and Takehiko Yokomizo, and Takao Shimizu, and Masataka Majima
July 1983, Biochemical and biophysical research communications,
Sohei Ito, and Yoshiya Ito, and Hiroyuki Katagiri, and Tatsunori Suzuki, and Sumio Hoka, and Takehiko Yokomizo, and Takao Shimizu, and Masataka Majima
April 1985, Biochemical and biophysical research communications,
Sohei Ito, and Yoshiya Ito, and Hiroyuki Katagiri, and Tatsunori Suzuki, and Sumio Hoka, and Takehiko Yokomizo, and Takao Shimizu, and Masataka Majima
November 1989, The Journal of biological chemistry,
Sohei Ito, and Yoshiya Ito, and Hiroyuki Katagiri, and Tatsunori Suzuki, and Sumio Hoka, and Takehiko Yokomizo, and Takao Shimizu, and Masataka Majima
December 2015, Biochemistry and biophysics reports,
Sohei Ito, and Yoshiya Ito, and Hiroyuki Katagiri, and Tatsunori Suzuki, and Sumio Hoka, and Takehiko Yokomizo, and Takao Shimizu, and Masataka Majima
February 2004, The British journal of ophthalmology,
Sohei Ito, and Yoshiya Ito, and Hiroyuki Katagiri, and Tatsunori Suzuki, and Sumio Hoka, and Takehiko Yokomizo, and Takao Shimizu, and Masataka Majima
August 2018, Science signaling,
Sohei Ito, and Yoshiya Ito, and Hiroyuki Katagiri, and Tatsunori Suzuki, and Sumio Hoka, and Takehiko Yokomizo, and Takao Shimizu, and Masataka Majima
June 2020, Arthritis & rheumatology (Hoboken, N.J.),
Sohei Ito, and Yoshiya Ito, and Hiroyuki Katagiri, and Tatsunori Suzuki, and Sumio Hoka, and Takehiko Yokomizo, and Takao Shimizu, and Masataka Majima
July 2017, Kidney international,
Sohei Ito, and Yoshiya Ito, and Hiroyuki Katagiri, and Tatsunori Suzuki, and Sumio Hoka, and Takehiko Yokomizo, and Takao Shimizu, and Masataka Majima
January 1987, Methods in enzymology,
Copied contents to your clipboard!